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Population–level effectiveness of PMTCT 
Option A on early mother–to–child (MTCT) 
transmission of HIV in South Africa: 
implications for eliminating MTCT  
Background Eliminating mother–to–child transmission of HIV (EMTCT), 
defined as ≤50 infant HIV infections per 100 000 live births, is a global 
priority. Since 2011 policies to prevent mother–to–child transmission of 
HIV (PMTCT) shifted from maternal antiretroviral (ARV) treatment or 
prophylaxis contingent on CD4 cell count to lifelong maternal ARV treat-
ment (cART). We sought to measure progress with early (4–8 weeks post-
partum) MTCT prevention and elimination, 2011–2013, at national and 
sub–national levels in South Africa, a high antenatal HIV prevalence set-
ting ( ≈ 29%), where early MTCT was 3.5% in 2010.
Methods Two surveys were conducted (August 2011–March 2012 and 
October 2012–May 2013), in 580 health facilities, randomly selected af-
ter two–stage probability proportional to size sampling of facilities (the 
primary sampling unit), to provide valid national and sub–national–(pro-
vincial)–level estimates. Data collectors interviewed caregivers of eligible 
infants, reviewed patient–held charts, and collected infant dried blood 
spots (iDBS). Confirmed positive HIV enzyme immunoassay (EIA) and 
positive total HIV nucleic acid polymerase chain reaction (PCR) indicated 
infant HIV exposure or infection, respectively. Weighted survey analysis 
was conducted for each survey and for the pooled data.
Findings National data from 10 106 and 9120 participants were analyzed 
(2011–12 and 2012–13 surveys respectively). Infant HIV exposure was 
32.2% (95% confidence interval (CI) 30.7–33.6%), in 2011–12 and 
33.1% (95% CI 31.8–34.4%), provincial range of 22.1–43.6% in 2012–
13. MTCT was 2.7% (95% CI 2.1%–3.2%) in 2011–12 and 2.6% (95% 
CI 2.0–3.2%), provincial range of 1.9–5.4% in 2012–13. HIV–infected 
ARV–exposed mothers had significantly lower unadjusted early MTCT 
(2.0% [2011–12: 1.6–2.5%; 2012–13:1.5–2.6%]) compared to HIV–in-
fected ARV–naive mothers [10.2% in 2011–12 (6.5–13.8%); 9.2% in 
2012–13 (5.6–12.7%)]. Pooled analyses demonstrated significantly low-
er early MTCT among exclusive breastfeeding (EBF) mothers receiving 
>10 weeks ARV prophylaxis or cART compared with EBF and no ARVs: 
(2.2% [95% CI 1.25–3.09%] vs 12.2% [95% CI 4.7–19.6%], respective-
ly); among HIV–infected ARV–exposed mothers, 24.9% (95% CI 23.5–
26.3%) initiated cART during or before the first trimester, and their early 
MTCT was 1.2% (95% CI 0.6–1.7%). Extrapolating these data, assum-
ing 32% EIA positivity and 2.6% or 1.2% MTCT, 832 and 384 infants 
per 100 000 live births were HIV infected, respectively.
Conclusions: Although we demonstrate sustained national–level PMTCT 
impact in a high HIV prevalence setting, results are far–removed from 
EMTCT targets. Reducing maternal HIV prevalence and treating all ma-
ternal HIV infection early are critical for further progress.











Eliminating mother–to–child transmission of HIV (EMTCT) 
is pivotal to improving child survival in high HIV–burden, 
resource–limited settings [1]. South Africa, an archetypal 
high HIV prevalence, middle–income country, with social 
and political idiosyncrasies after an apartheid history, has 
prioritised EMTCT. Since 2014 this has been defined as <5% 
mother to child transmission of HIV (MTCT) at final end-
point in breastfeeding populations, ≤50 new infant HIV in-
fections per 100 000 live births, ≥95% coverage of antenatal 
care among all women, ≥95% coverage of HIV testing and 
receipt of results and ≥90% coverage of antiretroviral drugs 
among HIV positive pregnant women [2,3]. Globally, strate-
gies to prevent MTCT (PMTCT) are guided by a comprehen-
sive four–prong approach, namely: (i) primary prevention 
of incident HIV infections; (ii) prevention of unplanned 
pregnancies; (iii) antiretroviral (ARV) drug interventions, 
and (iv) care, treatment and support, which aims to integrate 
PMTCT interventions into routine maternal, newborn and 
child health services [4].
Early, long–term triple combination antiretroviral therapy 
(cART) among HIV–positive women with higher CD4 cell 
counts (250–500 cells/mm3), or extended infant antiretro-
viral (ARV) prophylaxis have increased the impact of prong 
(iii) [5–7]. In 2010, the World Health Organization (WHO) 
PMTCT update recommended PMTCT Option “A” or “B” 
[8]: “A” provides antiretroviral prophylaxis (ARVP) from 
14 weeks gestation for HIV–infected pregnant women with 
CD4 cell counts >350 cells/mm3 and infant nevirapine 
(NVP) prophylaxis throughout breastfeeding; or lifelong 
cART for HIV–infected pregnant women with CD4 cell 
counts ≤350 cells/mm3 or WHO stage 3–4 disease with 6 
weeks of infant NVP prophylaxis; “B” provides cART dur-
ing breastfeeding for all HIV–positive pregnant and lactat-
ing women with six weeks infant NVP or continued ma-
ternal cART beyond breastfeeding cessation if maternal 
CD4 cell count ≤350 cells/mm3or WHO stage 3–4 disease. 
Since 2013 a rapid shift to PMTCT Option B+ has oc-
curred, and 18 of the 22 Global Plan priority countries 
(countries that house >90% of the world’s population of 
pregnant HIV positive women) have either endorsed, im-
plemented or conducted national scale–up of PMTCT Op-
tion B+ [9]. “B+” has reduced final MTCT to <2% in non–
breastfeeding countries [10].
South Africa’s national PMTCT program began with mater-
nal and infant single dose NVP (sdNVP) in 2002, and tran-
sitioned to dual ARV therapy in February 2008, to WHO 
PMTCT Option A in April 2010, PMTCT Option B in April 
2013 and PMTCT Option B+ in January 2015 [11].
Between 2001 and 2010, in resource–limited, high HIV 
prevalence countries, such as South Africa, rigorous routine 
measurements of national PMTCT impact and trends were 
simply unavailable. In 2010, using cross–sectional non–
routine surveillance methodology at immunisation service 
delivery points we conducted the first national PMTCT ef-
fectiveness evaluation in South Africa, which documented 
a 3.5% (95% CI 2.9–4.1%) risk of MTCT, measured at 4–8 
weeks postpartum (median 6 weeks), nationally under the 
2008 PMTCT policy [12]. This paper presents the results 
of two subsequent national surveys, conducted to measure 
national and provincial–level PMTCT impact, measured 
17–24 (August 2011–March 2012) and 31–38 (October 
2012–May 2013) months after implementing PMTCT Op-
tion A, and during the first 2 months (April–May 2013) of 
transitioning to PMTCT Option B. During this time, the 
South African national PMTCT program aimed to reduce 
MTCT to less than 2% and less than 5% at six weeks and 
18 months postpartum, respectively.
METHODS
The methods have been explained in detail elsewhere 
[11,13]. In summary, two cross–sectional, facility–based, 
national epidemiological surveys were conducted between 
August 2011–March 2012 and October 2012–May 2013. 
Public health non–mobile facilities offering infant immun-
isation services in each of the nine provinces were stratified 
according to their six–week annual immunisation numbers 
and antenatal HIV prevalence [12,14]. Specifying relative 
precisions of 30% to 50% for the expected MTCT rate 
across provinces plus a design effect of 2 yielded a total de-
sired sample size of 12 200 infant dried blood spot speci-
mens (iDBS). Stratified two–stage sampling was used with 
facilities sampled with probability proportional size and 
with replacement [15]. At the second stage a fixed number 
of infants per facility, representing the median number of 
infants expected within the sampling window (three weeks 
in 8 provinces; four weeks in the sparsely populated, low 
HIV prevalence Northern Cape province), were sampled 
to ensure a self–weighting sample at provincial level. Data 
were gathered using a questionnaire adapted from several 
validated tools [13,16,17]. Trained study nurses recruited 
eligible consented infants (aged 4–8 completed weeks; re-
ceiving their six–week immunisation; not needing emer-
gency care) and their caregivers [12]. Data on ARV expo-
sure and infant feeding were self–reported [12]. Trained 
supervisors used standard operating procedures to moni-
tor field work. Infants (not mothers) were tested for HIV 
antibodies to infant HIV exposure [11,13].
All infant dried blood spots (iDBS) were tested at the Na-
tional Institute for Communicable Diseases, Johannesburg, 
using standardised accredited procedures, namely Enzyme 
immunoassay (EIA) (Genscreen HIV1/2 Ab EIA Version 2, 
Bio–Rad Laboratories, Schiltigheim, France) to detect HIV 
antibodies. All antibody–positive and 10% of negative 
specimens were re–tested using a second EIA (Vironostika 
HIV Uni–form II plus O, bioMérieux Clinical Diagnostics, 
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Marcy–L’Etoile, France). Discordant results were re–pro-
cessed using Western blot (GS HIV–1, Bio–Rad, Schilt-
igheim, France). iDBS with concordant positive or discor-
dant EIA results or from self–reporting HIV–positive 
mothers were tested using a qualitative total nucleic acid 
Polymerase Chain Reaction (PCR) to determine infant’s 
HIV infection (COBAS AmpliPrep/COBAS TaqMan (CAP/
CTM) Qualitative assay version 1.0, Roche Diagnostics, 
Branchburg NJ, USA).
For data analysis sample weights were calculated that con-
sisted of two components: first realization weights were 
calculated depending on the realization within the strata of 
each province and second provincial weights. For the lat-
ter weight the number of live–births recorded across the 
nine provinces pertaining to the survey year was used. The 
sample weight was the product of realization weight and 
provincial weight and represents the number of live births 
the observed participant represents. The survey analysis 
took into account stratification, different sampling stages, 
the finite number of primary sampling units (PSU) and the 
design effect. Data were analyzed using SAS (SAS Institute 
N Carolina, Cary NC, USA) version 9.2and 9.4.
During data analysis self–reported maternal antiretroviral 
uptake was classified into three main groups with nine 
sub–groups (Figure 1).
Early MTCT by ARV category was initially measured using 
ARV definitions from Figure 1. Thereafter to facilitate com-
parison with the 2010 survey antiretroviral exposure was 
re–categorised into three main groups with six main cate-
gories, namely (i) “advanced regimen” group including 
mothers on cART or Azidothymidine (AZT) for >10 weeks 
and infant on sdNVP and/or AZT at birth (ARVP >10wks); 
(ii) “other ARV regimen” group including mothers on AZT 
for ≤10 weeks and infants on sdNVP and/or AZT at birth 
(ARVP ≤10 weeks) or mothers or infants (but not both) on 
any ARVs (incomplete ARVP) and (iii) “no known ARV 
group” including mothers and infants on no ARVs or with 
missing ARV information) [11].
Self–reported infant feeding was categorised using WHO 
definitions: exclusive breastfeeding (EBF), avoiding breast-
feeding (FF) and mixed breastfeeding (MBF) [18].
Simple logistic regression followed by multivariable logistic 
regression was conducted to examine risk factors for early 
MTCT using pooled data from the 2011-12 and 2012-13 
surveys. Clinically important predictors and risk factors 
with P < 0.25 in univariate unweighted analysis were in-
cluded in the preliminary main effects model. Variables 
with P < 0.05 or those that changed the odds ratio of the 
key exposure variable by 10% or those that were thought 
to be important independent predictors of MTCT in theo-
retical models were included in the penultimate model. 
The final model was selected based on model fit statistics 
(the best fit) with the lowest likelihood ratio and a signifi-
cant model chi–square test (P ≤ 0.05).
Ethical approval was obtained from the Medical Research 
Council and the United States Centers for Disease Control 
and Prevention. All caregivers included in analyses provid-
ed informed consent.
Figure 1. Classification of antiretroviral uptake 2011–2012 and 2012–13. Maternal self-reported antiretroviral uptake was 
classified into three overall groups with sub-categories in each group. AZT – azidothymidine, ARV – antiretroviral.












In the 2011–12 and 2012–13 surveys, respectively, 11 377 
and 10 533 participants were screened and 10 482 and 
9679 were enrolled; of the enrolled participants, iDBS were 
available on 10 106 (96.5%) and 9120 (94.2%) infants re-
spectively, yielding a sample realization of 83% and 75% 
(Table 1). Provincial sample realization ranged from 73%–
89% in 2011–12 and 56%–91% in 2012–13. The lower 
sample realization in 2012–13 is explained by the late 
(year–end) start date, vaccine stock–outs, facility changes 
from daily immunisation to weekly immunisation days and 
increased use of mobile services.
The weighted PMTCT cascade
Among all mothers self–reported weighted uptake of ante-
natal HIV testing was 98.3% (95% CI 98.0%–98.6%) in 
2011–12 and 95.5% (95% CI 95.0–96.0%) in 2012–13 
(Figure 2). In both surveys 99.4–99.8% of tested mothers 
received their results. This demonstrated that in 2012–13 
almost 95% of all mothers were tested and received their 
HIV test results.
Among self–reported HIV–positive mothers 86.4% (95% 
CI 84.2–88.7%) and 92.1% (95% CI 90.7%–93.5%) re-
ported being tested for CD4 cell count in 2011–12 and 
2012–13, respectively, and 77.4% (95% CI 74.9–80%) and 
65.9% (95% CI 63.3–68.6) reported knowing their CD4 
results. The median reported CD4 cell count was 359 cells/
mm3 (interquartile range IQR 240–499) in 2011–12 and 
372 cells/mm3 (IQR 264–500) in 2012–13.
The proportion of self–reported HIV positive women re-
ceiving maternal cART increased by 12.9%, from 41.9% 
(95% CI 39.7–44.2%) in 2011–12 to 54.8% (95% CI 
52.6%–57.0%) in 2012–13, while receipt of any maternal 
or infant prophylaxis dropped by 8.1%, from 52.0% (95% 
CI 49.7–54.2%) in 2011–12 to 43.9% (95% CI 41.8–
46.1%) in 2012–13. Due to the increased cART uptake 
overall, ARV coverage among self–reported HIV positive 
women increased from 93.9% in 2011–12 to 98.7% in 
2012–13.
Among EIA positive infants: 85.9% (95% CI 84.3–87.5) 
and 91.3% (95% CI 90.0–92.6%) were born to mothers 
who reported receiving any maternal antiretroviral therapy 
in 2011–12 and 2012–13 respectively; 93.4% (95% CI 
92.4–94.5%) and 94.0% (95% CI 92.9–95.1%) reported 
initiating infant NVP prophylaxis in 2011–12 and 2012–13 
respectively and 86.4% (95% CI 84.3–88.5%) and 91.4% 
(95% CI 95.1–96.2%) reported current infant NVP–use at 
the time of interview (six weeks postpartum); any breast-
feeding increased from 53.0% (95% CI 50.4–55.5%) in 
2011–12 to 72.2% (95% CI 70.1–74.2%) in 2012–13; EBF 
increased from 35.5% (95% CI 33.1–38.0%) in 2011–12 
to 54.1% (95% CI 51.9%–56.2%) in 2012–13 and MBF 
increased from 14.0% (12.3–15.7%) in 2011–12 to 20.5% 
(18.8–22.1%) in 2012–13. Avoiding breastfeeding de-
creased from 47.1% (44.9–49.3%) in 2011–12 to 27.7% 
(95% CI 25.6–29.7%) in 2012–13.
Weighted Infant HIV exposure and MTCT
In 2011–12 and 2012–13 self–reported maternal HIV pos-
itivity was 29.5% (95% CI 28.0–32.2%) and 32.1% (95% 
CI 30.8–33.4%) respectively while infant EIA positivity 
was 32.2% (95% CI 30.7–33.6%) and 33.1% (95% CI 
31.8–34.4%) respectively (Table 1). The national popula-
tion–level risk of early MTCT measured among EIA posi-
tive infants was 2.7% (95% CI 2.1–3.2%) in 2011–12 and 
2.6% (95% CI 2.0–3.2%) in 2012–13. Early MTCT varied 
provincially from 2.0% (95% CI 0.6–3.3) to 6.1% (95% CI 
Table 1. Sample realization, infant HIV exposure and early MTCT at 6 weeks (range 4–8 weeks) postpartum: 2011–12 and 2012–13
Province August 2011 – MArch 2012 survey* october 2012 – MAy 2013 survey†
Sample realization 
number (%)










South Africa 10 106 (83%) 32.2 (30.7–33.6) 2.7 (2.1–3.2) 9120 (75%) 33.1 (31.8–34.4) 2.6 (2.0–3.2)
Eastern Cape 1194 (85%) 32.0 (29.6–35.5) 3.8 (2.1–5.5) 1035 (74%) 29.0 (25.1–32.9) 2.4 (1.1–3.8)
Free State 1056 (81%) 30.9 (28.6–33.3) 3.8 (2.3–5.3) 868 (67) 34.2 (30.6–37.7) 2.8 (1.5–4.1)‡
Gauteng 1607 (89%) 33.1 (29.8–36.4) 2.1 (0.9–3.4) 1637 (91%) 34.0 (30.6–37.4) 2.2 (1.3–3.1)
Kwa–Zulu Natal 1052 (75%) 44.4 (39.8–48.9) 2.1 (0.9–3.3) 1060 (76%) 43.6 (39.5–47.8) 2.9 (1.3–4.6)
Limpopo 1070 (76%) 23.0 (19.9–26.2) 3.1 (1.2–4.9) 1225 (88%) 25.2 (21.8–28.7) 2.1 (0.6–3.6)
Mpumalanga 1210 (76%) 35.6 (33.3–37.8) 3.3 (2.2–4.5) 898 (56%) 37.6 (33.6–41.7) 1.5 (0.6–2.3)‡
Northern Cape 506 (72%) 15.1 (12.7–17.5) 6.1 (2.5–9.6)‡ 426 (61%) 20.9 (15.6–26.2) 2.2 (0.4–4.1)‡
North West 1037 (86%) 30.8 (28.5–33.1) 2.6 (1.1–4.0) 781 (65%) 31.4 (27.8–35.0) 5.4 (3.4–7.4)‡
Western Cape 1374 (98%) 17.8 (14.8–20.8) 2.0 (0.6–3.3) 1190 (85%) 22.1 (17.8–26.6) 1.9 (0.4–3.3)
MTCT – mother–to–child transmission, CI – confidence interval
*Conducted during months 17 (August 2011) to 24 (March 2012) after PMTCT Option A became policy.
†Conducted during months 31–38 after PMTCT Option A was adopted and includes the first 2 months (April and May 2013) of PMTCT Option B 
policy implementation.
‡Sample realization <70%, thus these MTCT estimates may be subject to bias.
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2.5–9.6) in 2011–12 and from 1.5% (95% CI 0.6–2.3) to 
5.4% (95% CI 3.4–7.4) in 2012–13 (Table 1). The unad-
justed pooled early MTCT (2011–12 and 2012–13) was 
2.6% (2.2–3.1%).
In 2011–2012 and 2012–13 among “mothers receiving any 
PMTCT intervention(s)”, early MTCT was 2.0%, (95% CI 
1.6–2.5% and 1.5–2.6%, respectively); among mothers 
who did not know that their infants were EIA–positive, 
early MTCT was 10.2% in 2011–2012 (95% CI 6.5–
13.8%) and 9.2% in 2012–2013 (95% CI 5.6–12.7%), re-
spectively (Figure 3).Overall, the risk of unadjusted MTCT 
differed significantly by antiretroviral exposure (Table 2, 
P < 0.0001 for Columns A–C). Columns B and C present 
early MTCT using the pooled 2011–13 data set analyzed 
according to the 2010 survey ARV categories [11], to fa-
cilitate comparison. Of note is that early MTCT decreased 
to 1.2% (0.6–1.7) among HIV positive mothers who com-
menced cART in the first trimester or before.
Table 3 illustrates that controlling for maternal age, socio–
economic status (SES), marital status, education, gestation-
al age at first ANC visit, total number of lifetime pregnan-
cies, whether or not the current pregnancy was planned, 
province, survey year and whether or not the infant weighed 
less than 2.5kg at birth, the adjusted odds of early MTCT 
increased significantly if mother started ARVP in the second 
trimester (after 12 weeks’ gestation) or if only mother or 
baby or neither received antiretroviral drugs, compared to 
mothers who received cART in the first trimester or before. 
There were no additional significant MTCT differences be-
tween any of the other ARVP groups, although this could 
relate to small sample sizes. However the point estimates 
for early MTCT tended to increase as ARV exposure de-
creased.
Table 4 demonstrates the protective effect of advanced an-
tiretroviral regimens on early MTCT within exclusively 
breastfeeding populations (2.17% [1.23–3.09%]) in the EBF 
group with advanced regimens compared with 12.17% 
(4.7–19.6%) in the no ARV group. Among EBF women who 
initiated cART in the first trimester or before, early MTCT 
was 0.82% (0.06–1.58%), data not shown in the table.
DISCUSSION
These PMTCT surveillance studies conducted at national 
and subnational (provincial) levels, in public health facili-
ties that provide care for the majority of South Africa’s chil-
dren, demonstrated that population–level early MTCT was 
sustained at 2.6%, 17–24 and 31–38 months after PMTCT 
Option A policy was adopted. HIV testing uptake was 95% 
and at least 99.7% of tested mothers received their HIV test 
results; thus almost 95% of all mothers receive their HIV 
test results. Therefore the ≥95% validation target for HIV 
testing uptake has just about been met in 2012–13. Mater-
nal antiretroviral uptake among mothers with EIA positive 
infants was 91.3% (90.0–92.6%) in the 2012–13 survey, 
also meeting this EMTCT validation target at national level.
Although the 2.6% was a reduction from previous MTCT 
estimates in South Africa, these data show that the nation-
al target of <2% at 6 weeks postpartum was not achieved. 
Uptake of first trimester cART reduced early MTCT to 
Figure 2. Weighted uptake along the PMTCT (prevent mother–to–child transmission) cascade among self–reported HIV positive 
women 2011–2012 and 2012–2013. PE – point estimate; LL – lower limit of 95% confidence interval (CI); UL – upper limit of 95% 
CI, cART – combination antiretroviral therapy, AZT – azidothymidine, ARV – antiretroviral, NVP – nevirapine.











Table 2. MTCT by various antiretroviral exposures: pooled 2011–12 and 2012–13 data





of hiv Positive infAnts 
(weighted hiv Positive 
frequency)
weighted Mtct (%) 
(coluMn A)
weighted Mtct (%) 
According to Arv grouPs 
generAted in the 2010 PAPer 
[11] (coluMn b)
weighted Mtct (%) 
According to Arv grouPs 




(1a) cART commenced in 1st trimester 
or before with infant postnatal 
prophylaxis
1472 (187 986) 19 (2201) 1.17 (0.61–1.72) 2010 1a, 1.60 
(1.15–2.05)
1.84 (1.44–2.25)
(1b) cART commenced in 2nd trimester 
with infant prophylaxis
727 (96 677) 14 (1638) 1.69 (0.76–2.62)
(1c) cART commenced in 3rd trimester 
with infant prophylaxis
163 (35 699) 2 (330) 0.92 (0.00–2.22)
(1d) AZT prophylaxis commenced in 
1st trimester with infant prophylaxis 
(ARVP)
821 (102 640) 20 (2619) 2.54 (1.28–3.80) 2010 1b, 2.30 
(1.42–3.2)
(1e) AZT prophylaxis commenced in 
2nd trimester with prophylaxis (ARVP)
1087 (151 221) 26 (3515) 2.31 (1.42–3.21)
Other ARV regimen group:
(2a) AZT prophylaxis commenced in 
3rd trimester with prophylaxis (ARVP)
205 (27 856) 2 (368) 1.32 (0.00–3.16) 2010 2a, 1.32 
(0.00–3.16)
2.49(1.36–3.61)
(2b) mothers or infants (but not both) 
received any ARVs (incomplete ARVP)
507 (62 419) 19 (2446) 3.90 (1.88–5.92) 2010 2b, 3.90 
(1.88–5.92)
No known ARV group:
(3a) mothers and infants reported 
receiving no ARV
63 (8119) 8 (995) 2010 3a, 11.40 (3.75–19.05)
(3b) missing ARV information 643 (76 929) 48 (5875) 2010 3b, 7.28 (5.03–9.53)
MTCT – mother–to–child transmission, cART – combination antiretroviral therapy, AZT – azidothymidine, ARV – antiretroviral, ARVP – antiretroviral 
prophylaxis
Figure 3. MTCT (mother–to–child transmission) measured in 2011–12 and 2012–13, with and without any PMTCT (prevent 
mother–to–child transmission) intervention. EIA – enzyme immunoassay.
1.17% (0.61–1.72). Extrapolating these results to num-
bers, assuming 32% infant HIV exposure among 100 000 
live births, 2.6% early MTCT means that by 6 weeks post-
partum, 832 infants per 100 000 live births were HIV in-
fected, and 1.17% early MTCT means that 384 infants per 
100 000 live births were HIV infected. These extrapolations 
are far higher than the EMTCT target of ≤50 HIV infected 
infants per 100 000 live births, and are driven by the high 
HIV prevalence in South Africa.; These stark findings illus-
trate the importance of a public health approach to PMTCT, 
which locates all PMTCT interventions within a comprehen-
sive framework aiming to reduce new HIV infections among 
young women of reproductive age, thus reducing antenatal 
HIV prevalence. Although the paper confirms that early 
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Table 3. Associations between key PMTCT interventions and weighted perinatal infant HIV positive status in HIV exposed infants, 
South Africa, pooled data 2011–2013
indicAtors frequency of 
hiv exPosed 
infAnts with Pcr 
results*, n = 5889 
(nw = 762 314)
frequency of 
hiv infected 
infAnt n = 160, 
(nw = 20 130)
unAdjusted or,  
(95% ci)
Adjusted or†,  
Model 1§
Adjusted or†,  
Model 2||
Adjusted or†,  
Model 3¶
Adjusted or‡, finAl 
Model**
CD4:††
≤350 cells/mm3 1682 (224 217) 35 (3977) 0.87 (0.51–1.50) 0.98 (0.42–2.05) 0.96 (0.46–2.01)
>350 cells/mm3 1927 (258 908) 35 (5258) Ref Ref Ref
Missing 2230 (272 433) 90 (10 895) 2.01 (1.30–3.1) 0.79 (0.40–1.55) 0.78 (0.40–1.51)
Advanced regimen group (as defined in Figure 1):
(1a) 1472 (187 986) 19 (2201) Ref Ref Ref
(1b) 727 (96 677) 14 (1638) 1.45 (0.70–3.005) 1.84 (0.81–4.18) 1.82 (0.8–4.1)
(1c) 163 (35 699) 2 (330) 0.79 (0.18–3.46) 0.43 (0.05–3.56) 0.44 (0.05–3.56)
(1d) 821 (102 640) 20 (2619) 2.21 (1.08–4.52) 2.06 (0.78–5.44) 2.07 (0.79–5.43)
(1e) 1087 (151 221) 26 (3515) 2.01 (1.09–3.7) 2.43 (1.13–5.23) 2.37 (1.1–5.15)‡‡
Other ARV regimen group (as defined in Figure 1):
(2a) 205 (27 856) 2 (368) 1.13 (0.25–5.06) 1.32 (0.25–6.83) 1.25 (0.24–6.39)
(2b) 507 (62419) 19 (2446) 3.44 (1.66–7.14) 4.12 (1.53–11.43) 4.16 (1.53–11.35)‡‡
No known ARV group (as defined in Figure 1):
(3a) 63 (8119) 8 (995) 11.78 (4.83–28.75) 9.04 (2.14–38.19) 9.0 (2.17–37.38)‡‡P
(3b) 643 (76 929) 48 (5875) 7.0 (3.85–12.65) 11.90 (4.64–30.49) 11.58 (4.46–30.05)‡‡
Infant feeding practices:
FF 2212 (289 615) 46 (6218) Ref Ref Ref
EBF 1452 (192 577) 41 (6044) 1.77 (1.09–2.87) 1.98 (1.08–3.66) 1.80 (0.95–3.42)
Mixed BF 365 (46 619) 12 (1379) 1.67 (0.88–3.12) 1.48 (0.76–2.88) 1.04 (0.52–2.10)
Delivery type:
Cesarean 1322 (178 656) 31 (4385) Ref Ref Ref
Vaginal 4404 (563 637) 124 (15234) 0.91 (0.58–1.42) 0.46 (0.20–1.05) 0.82 (0.43–1.59)
PMTCT – prevent mother–to–child transmission, EBF – exclusive breastfeeding, FF – formula feeding (no breastmilk), MF – breastfeeding with other 
fluids or solids, ARV – antiretroviral, CI – confidence interval, OR – odds ratio, Nw – weighted population number, Ref – reference group
*55 (unweighted) exposed infants with missing HIV DNA test results excluded from this analysis.
†Adjusted for maternal age, SES, marital status, education, gestational age at first ANC visit, total number of lifetime pregnancies, whether or not the 
current pregnancy was planned, province, survey year and whether or not the infant weighed less than 2∙5kg at birth.
‡Adjusted for maternal age, SES, marital status, education, gestational age at first ANC visit, total number of lifetime pregnancies, whether or not the 
current pregnancy was planned, province, survey year and whether or not the infant weighed less than 2∙5kg at birth.
§Observations used = 3571; –2LL = 107 170; Wald P < 0.0001.
||Observations used = 3571; –2LL = 101 093; Wald P < 0.0001.
¶Observations used = 3571; –2LL = 101 775; Wald P < 0.0001.
**Observations used = 3571; –2LL = 95 350.75; Wald P < 0.0001.
††Self–reported databased on mother’s last CD4 cell count.
‡‡Significant relationship between characteristic and MTCT.
Table 4. Stratified analysis of MTCT by infant feeding practice and PMTCT regimen
feeding PAttern 
over Previous 8 
d At 6 weeks
chArActeristic AdvAnced regiMen grouP*, 
P = 0.27
other Arv regiMen 
grouP*, P = 0.44
no known Arv grouP*, 
P = 0.05
EFF Unweighted number–UWNo. HEI (weighted number WNo HEI) 1770 (234 655) 235 (30 524) 210 (25 226)
UWNo HIV positive infants–HPI
(WNo HPI)
29 (3383) 7 (739) 10 (1097)
Weighted MTCT risk % (95% CI) 1.44 (0.92–1.97) 2.40 (0.53–4.31) 4.35 (1.39–7.30)
EBF UWNo. HIV–exposed infants (HEI)
(WNo HEI)
1166 (1554) 196 (25 414) 97 (12 775)
UWNo HPI
(WNo HPI)
25 (3374) 6 (1115) 10 (1555)
Weighted MTCT risk % (95% CI) 2.17 (1.25–3.09) 4.39 (0.57–8.21) 12.17 (4.7–19.6)
MBF UWNo. HEI
(WNo HEI)
227 (29 465) 53 (6171) 93 (11 926)
UWNo HPI
(WNo HPI)
3 (329) 3 (326) 6 (726)
Weighted MTCT risk % (95% CI) 1.12 (0.0–2.46) 5.27 (0–11.04) 6.08 (1.04–11.12)
MTCT – mother–to–child transmission, PMTCT – prevent mother–to–child transmission, EFF – formula feeding (no breastmilk), EBF – exclusive breast-
feeding, MBF – breastfeeding with other fluids or solids, UWNo – unweighted number, WNo – weighted number; HEI – HIV–exposed infants, HPI – 
HIV positive infants, CI – confidence interval
*As defined in Figure 1.











cART initiation is feasible and critical for further reducing 
MTCT in high HIV prevalence settings, it substantiates the 
view that prong 3 can reduce but not eliminate MTCT.
Advanced antiretroviral therapy (any cART or ARVP to 
mother before the third trimester, with infant prophylaxis) 
compared to no PMTCT drug interventions, reduced the 
MTCT associated with exclusive breastfeeding (EBF) from 
12.17% to 2.17% (1.25–3.09%), and first trimester cART 
reduced EBF–associated MTCT to 0.82%.
The overall MTCT risk declined by 22% from the 3.5% 
(95% CI 2.9–4.2%) achieved under dual prophylaxis/2006 
WHO PMTCT guidelines/2008 SA PMTCT guidelines 
[11]. Similarly any cART–use under PMTCT Option A pol-
icy demonstrated tendency toward lower early MTCT (Col-
umn B in Table 2, 1.6% [1.15–2.05%]) compared with 
cART–use reported in the 2010 survey [11], under 2008 
SA PMTCT guidelines) (2.1% [95% CI 1.2–3.0%]), illus-
trating the population–level effect of cART initiation at 
higher CD4 cell counts. The results confirm that PMTCT 
impact can be sustained at national level, despite increas-
ing breastfeeding uptake. The increased breastfeeding be-
tween 2011–12 and 2012–13 could be explained by the 
August 2011 national policy change (South African Tsh-
wane Declaration of Support for Breastfeeding) to support-
ing breastfeeding among all women, regardless of HIV sta-
tus. Formula feeding was only supported in special 
circumstances and for medical indications. The phasing out 
of free commercial infant formula for HIV positive women, 
as part of the PMTCT program began in January 2012 and 
free formula was fully withdrawn by September 2012.
This was the first national evaluation of PMTCT Option A 
in a breastfeeding setting. Interestingly, the two popula-
tion–level surveys yield lower MTCT estimates compared 
with recent clinical trials conducted in breastfeeding set-
tings [7]. Short–course maternal cART or long–course ma-
ternal ARVP with infant extended or short–term prophy-
laxis reduced early MTCT to 3.3%, 4.5% or 6.5%. The 
former result is from the Kesho Bora study which offered 
cART from 28–36 weeks gestation till 6 months postpar-
tum to women with CD4 cell counts between 200 and 500 
cells/mm3 [19]. The latter two results are from the Breast-
feeding Antiretroviral and Nutrition (BAN) study which 
provided daily infant NVP or maternal cART from 1 week 
till 6 months postpartum, respectively [20].
Also of note is that these population–based findings do not 
corroborate modeling estimates, which suggest that reduc-
ing MTCT to <2% at 6 weeks and <5% at the final endpoint 
can only be achieved with >90% coverage with ART, great-
er than 50% reduction in incident HIV infection and 0% 
unmet need for family planning [21]. In the pooled analy-
sis MTCT under PMTCT Option A was <2% among wom-
en who received cART before or during the first trimester 
(1.17%, 0.6–1.7%). However our calculations demonstrate 
that number of HIV infected children remain unacceptably 
high, being driven by high maternal HIV prevalence.
Among “middle–income” countries EMTCT has only been 
reported from Cuba, a non–priority country for MTCT 
elimination, where adult and antenatal HIV prevalence is 
very low (<0.1%) and a comprehensive national PMTCT 
program began in 1986, transitioning to PMTCT Option 
B+ in 2011 [22].
The results of our national surveys were limited by low 
provincial sample realization, which was addressed by 
weighting the data; exclusion of sick or dead infants, which 
may have over–estimated PMTCT effectiveness; lack of ini-
tial and current CD4 cell count and viral load data which 
precluded more in–depth analysis of MTCT by viral load 
or CD4 cell count, use of self–reported data on ARV use, 
and few events (outcomes) within antiretroviral regimen 
groups which reduced precision. Notwithstanding these, 
consistency between the PMTCT survey’s self–reported 
HIV sero–prevalence (29.5%) and anonymous annual an-
tenatal survey’s HIV sero–prevalence (29.5%), despite the 
use of different sampling frames, confirms the robustness 
of the self–reported data.
CONCLUSIONS
Three years after changing to PMTCT Option A, a sustained 
lower risk of early MTCT was measured at population level. 
Despite the existence of a mature PMTCT program with in-
creasing cART coverage, there were still missed opportuni-
ties for PMTCT interventions particularly among undiag-
nosed HV positive mothers. MTCT was reduced to less than 
2% only among mothers who initiated cART during the first 
trimester or before. Despite a reduction in percentage MTCT, 
the number of infant HIV infections per 100 000 live births 
at six weeks postpartum, was above the global validation tar-
get. Eliminating unidentified maternal HIV infections 
[23,24], reducing maternal HIV prevalence and improving 
retention in HIV–related care (early cART initiation and ad-
herence) [25] are critical to closing current gaps.
These periodic surveys, conducted nationally among all 
children attending public health facilities for immunization 
regardless of their mothers HIV status, have been pivotal 
in tracking national and subnational PMTCT impact in 
South Africa. While routine systems are being strengthened 
to monitor PMTCT impact, national surveys, such as these 
reported in this paper, conducted every two to three years 
are key for tracking PMTCT impact. Where routine systems 
are strong, periodic surveys conducted every four to five 
years may be important to validate routine data.
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